| scholarly article | Q13442814 |
| P50 | author | David Harrison | Q56737485 |
| Annelien Zweemer | Q63923662 | ||
| Andrew H. Sims | Q39065426 | ||
| P2093 | author name string | S P Langdon | |
| C Kay | |||
| M Muir | |||
| M Hasmann | |||
| Y Nagumo | |||
| D Faratian | |||
| M Dodds | |||
| I Um | |||
| P2860 | cites work | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| Significance analysis of microarrays applied to the ionizing radiation response | Q24606608 | ||
| Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. | Q52848050 | ||
| Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. | Q54645242 | ||
| Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status | Q57217085 | ||
| Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer | Q62112715 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer | Q87356244 | ||
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas | Q28256478 | ||
| A new therapeutic antibody masks ErbB2 to its partners | Q28257173 | ||
| Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer | Q28257940 | ||
| Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling | Q28289659 | ||
| HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways | Q28299421 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation | Q33291042 | ||
| HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy | Q33517907 | ||
| Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. | Q34048134 | ||
| HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment | Q34111958 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Neoadjuvant trastuzumab induces apoptosis in primary breast cancers | Q34394358 | ||
| The basement membrane matrix in malignancy | Q35170435 | ||
| Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism | Q35558065 | ||
| Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers | Q35566231 | ||
| Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer | Q36398884 | ||
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 | ||
| Cytokines as a key component of cancer-related inflammation | Q37243051 | ||
| Beyond chemotherapy: targeted therapies in ovarian cancer | Q37399899 | ||
| Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. | Q37401557 | ||
| The future of targeted therapies in ovarian cancer | Q37547669 | ||
| Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 | ||
| G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer | Q38350126 | ||
| Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer | Q38419271 | ||
| Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole | Q38510967 | ||
| Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. | Q39542474 | ||
| Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 | ||
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells | Q40048205 | ||
| Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling | Q40181231 | ||
| 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth | Q40355484 | ||
| P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. | Q40550119 | ||
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 | ||
| A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer | Q40666631 | ||
| Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. | Q43254569 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Automated subcellular localization and quantification of protein expression in tissue microarrays. | Q52030096 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| trastuzumab | Q412616 | ||
| P304 | page(s) | 1779-1789 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer | |
| P478 | volume | 106 |
| Q37689036 | A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. |
| Q33750182 | Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer |
| Q41915916 | Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations. |
| Q91854733 | Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models |
| Q38103747 | Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells |
| Q91603678 | Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer |
| Q36557500 | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling |
| Q39042958 | In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells. |
| Q57105786 | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| Q35448716 | Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts |
| Q36387554 | NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. |
| Q39181880 | Network-based identification of key proteins involved in apoptosis and cell cycle regulation. |
| Q48102534 | Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. |
| Q38432883 | RNA-based ovarian cancer research from 'a gene to systems biomedicine' perspective. |
| Q35693161 | Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system |
| Q38704805 | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression |
| Q97686325 | Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies |
| Q38680412 | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression |
| Q42109090 | Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q38249126 | Targeting HER2 in ovarian and uterine cancers: challenges and future directions |
| Q61815424 | Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy |
| Q64084185 | The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation |
| Q40711411 | The prognostic of p27(kip1) in ovarian cancer: a meta-analysis |
Search more.